Welcome to the Bladder Cancer website! Please take a look around at the content of the journal and other features of this community portal, including joining the discussion thread about the latest challenging cases, or taking a look at the funding analyzer.

We are pleased to announce that, as of 2018, Bladder Cancer is classified as the official journal of the Bladder Cancer Advocacy Network (BCAN). Read more about this new partnership to support a readily accessible information platform to serve the bladder cancer research and clinical practice communities via the following link: http://tiny.cc/BLC-BCAN_PR

This study provides an overview and resources on the origin, pathological and molecular characteristics of commonly used human, murine and canine BC cell lines. The Venn diagram illustrates the 127 human bladder cancer cell lines analyzed in five panels. From: TCM Zuiverloon et al., Bladder Cancer, vol. 4, no. 2, pp. 169–183, 2018

This study undertakes a quantitative assessment of heterogeneity in bladder tumor MRI diffusivity, showing the ADC heterogeneity in the bladder tumor of a responder (upper) vs. a non-responder (lower). From: HT Nguyen et al., Bladder Cancer, vol. 3, no. 4, pp. 237–244, 2017

Investigating the impact of the proliferation biomarker Ki-67 in initial stage pTa urothelial carcinoma of the bladder. Examples of low (<10%, A) and strong (≥50%, B) staining of Ki-67 under 5 fold and 40 fold magnification. From: Breyer, et al., Bladder Cancer, vol. 3, no. 3, pp. 173–180, 2017

The synergistic relationship between immunotherapy and radiation. From Buchwald and Efstathiou. Bladder Cancer, vol. 1, no. 1, pp. 15–27, 2016